Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer

British Journal of Cancer

Volumn 77, Issue 7, 1998, Pages 1130-1136

  Berns, E M J J ^a   Van Staveren, I L ^a   Look, M P ^a   Smid, M ^a   Klijn, J G M ^a   Foekens, J A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer prognosis; DNA contact residue; Mutation; TP53

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RECURRENCE; CANCER SURVIVAL; CODON; DNA BINDING; FEMALE; GENE DISRUPTION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTIVARIATE ANALYSIS; NONSENSE MUTATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SILENT GENE; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 0031929915     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.187     Document Type: Article

References (25)

1. Andersen TI and Borresen AL (1995) Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Diagnos Mol Pathol 4: 203-211
2. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L and Borresen AL (1993) Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68: 540-548
3. Bergh J, Norberg T, Sjogren S, Lindgren A and Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1: 1029-1034
4. Berns PMJJ, Klijn JGM, Staveren Van IL, Portengen H, Noordegraaf E and Foekens JA (1992) Prevalence of amplification of lhe oncogenes c-myc, HER2/neu, and int-2 in thousand human breast cancers: relationships with steroid receptors. Eur J Cancer 28: 697-700
5. Berns EMJJ, Klijn JGM, Smid M, Van Staveren IL, Look MP, Van Putten WLJ and Foekens JA (1996) TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromos Cancer 16: 170-179
6. Borresen AL, Andersen TI, Eyfjord JE, Cornells RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S and Hartman S (1995) TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromos Cancer 14: 71-75
7. Carbone D, Chiba I and Mitsudomi T (1991) Polymorphism at codon 213 within the p53 gene. Oncogene 6: 1691
8. Cariello NF, Cui L, Beroud C and Soussi T (1994) Database and software for the analysis of mutations in the human p53 gene. Cancer Res 54: 4454-4460
9. Cho Y, Gorina S, Jeffery PD and Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DMA complex: understanding tumorigenesis. Science 265: 346-355
10. De Witte HH, Foekens JA, Lennerstrand J, Smid M, Look MP, Klijn JGM, Benraad T and Berns EMJJ (1996) Prognostic significance of TP53 accumulation in human primary breast cancer: Comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer 69: 125-130
11. Eortc Breast Cancer Cooperative Group (1973) Standard for the assessment of hormone receptors in human breast cancer. Eur J Cancer 9: 379-381
12. Friend S (1994) p53: A glimpse at the puppet behind the shadow play. Science 265: 334-335
13. Greenblatt MS, Bennet WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-1878
14. Haffner R and Oren M (1995) Biochemical properties and biological effects of p53. Genes Dev 5: 84-90
15. Harris CC (1996a) Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 28: 1442-1455
16. Harris CC (1996b) The 1995 Walter Hubert Lecture - molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer 73: 261-269
17. Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De Vries EM, Kovach JS and Sommer SS (1995) p53 Gene mutations inside and outside of exons 5-6: the patterns differ in breast and other cancers. Oncogene 10: 681-688
18. Hartmann A, Blaszyk H, Kovach JS and Sommer SS (1997) The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 13: 27-33
19. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481
20. Kinzler KW and Vogelstein B (1996) Life (and death) in a malignant tumour. Nature 379: 19-20
21. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
22. Prives C (1994) How loops, β sheets, and a helices help us to understand p53. Cell 78: 543-546
23. Putten VWLJ, Klijn JGM, Meijer-Van Gelder ME, Look MP and Foekens JA (1996) Multiparameter analysis of prognostic factors in breast cancer. Breast Cancer 209-215
24. Shiao YH, Chen VW, Scheer D, Wu XC and Correa P (1995) Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 55: 1485-1490
25. Velculescu VE and El-Deiry WS (1996) Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858-868